Journal of Clinical Oncology
Articles in this Issue
Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
12084 Background: Adolescents and young adults (AYA) with advanced cancer, including metastatic cancer, have a unique set of medical, social and psycholog...
Can we determine the mechanism behind cancer risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1RAs)?
10535 Background: Growing evidence suggests that GLP-1RAs may reduce cancer risk in patients with type 2 diabetes (T2D). Most studies have focused on obes...
A phase I study of TR64, a VEGFR/CSF1R/c-KIT small molecule inhibitor, for the treatment of advanced malignant solid tumors.
e15146 Background: Vascular endothelial growth factor receptors (VEGFRs) are highly expressed in many solid tumors and plays a key role in angiogenesis, w...
Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).
1032 Background: The antitumor activity of T-DXd for MBC is sub-optimally predicted by HER2 immunohistochemistry (IHC). We evaluated novel assays to quant...
Survival outcomes in early-stage cutaneous desmoplastic melanoma: A National Cancer Database analysis.
e21577 Background: Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by spindle-shaped tumor cells within a fibrous stroma. Factors i...
Initial report of memory avoidance whole brain radiotherapy to treat brain metastases: A prospective phase 2 trial.
2039 Background: A common approach for patients with extensive brain metastases requiring radiation is hippocampal avoidance whole brain radiotherapy (HA-...
Demographics, socioeconomic, and treatment patterns for adenocarcinoma with cartilaginous and osseous metaplasia: A National Cancer Database analysis.
e15705 Background: Adenocarcinoma with cartilaginous and osseous metaplasia is a rare and aggressive cancer. This variant is characterized by the presence...
The impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC).
1598 Background: Structural racism encompasses multiple intricate systems that generate and reinforce inequities amongst minoritized communities. Given th...
The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.
e15569 Background: Recent studies have shown an increased incidence of early-onset CRC (EO-CRC), particularly in advanced...
Plasma ANGPTL3, Apo CIII, leptin, and lipid levels in patients with metastatic prostate cancer.
e17054 Background: Abundant cholesterol supplies are required to sustain tumor growth and metastasis. Metastatic prostate cancers (PCa) are no exception....
Timing of neoadjuvant pembrolizumab infusion and pathologic complete response among patients with triple-negative breast cancer receiving the KEYNOTE-522 regimen.
e12616 Background: Recent studies have demonstrated that cancer cell metastasis, chemotherapy metabolism, and immune activation and response can be affect...
Real-world data on the effectiveness and toxicity of atezolizumab and bevacizumab as first-line therapy in patients with unresectable or metastatic hepatocellular carcinoma in Costa Rica.
e16189 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally. The combination of atezolizumab and bevaci...
A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi).
TPS12148 Background: Despite substantial improvements in survival, postmenopausal survivors of breast cancer remain at high risk of functional decline aft...
Investigating the role of ZEB2 upregulation in TAM polarization and immune modulation in EGFR-TKI resistant NSCLC.
e20669 Background: Immune checkpoint inhibitors (ICIs) pushed therapeutic strategy of NSCLC into a new era. Nevertheless, the clinical benefit of ICI ther...
Socio-economic and geographic survival disparities among children with lymphoma in the USA.
e22005 Background: The effect of socioeconomic status (SES) and place of residence on cancer survival has been extensively studied among adults. There is,...
Evaluation of <sup>68</sup> Ga-FAPI PET/CT and <sup>18</sup> F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC).
3071 Background: Fibroblast activation protein inhibitor (FAPI) radiolabeled with Gallium-68 or Fluorine-18 have emerged as promising tracers for targetin...
Neoadjuvant stereotactic radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV).
TPS4623 Background: Patients with muscle invasive bladder cancer (MIBC) may not be candidates for cisplatin-based chemotherapy based on their comorbiditie...
Clinical and molecular determinants of survival in pancreatic neuroendocrine tumors: A comprehensive analysis from SEER and TCGA databases.
e16355 Background: Neuroendocrine tumors (NETs) are the 3rd most common endocrine tumor, with pancreatic NETs (pNETs) accounting for 6% of all NETs. Next-...
Skewed offspring distribution of <i>TP53</i> pathogenic variants in Israeli Li-Fraumeni syndrome families.
10604 Background: Li-Fraumeni Syndrome (LFS) [OMIM #151623] is an autosomal dominant cancer predisposition syndrome caused primarily by germline pathogeni...
FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
3513 Background: Several smaller studies performed in later lines of treatment have suggested a potential benefit from anti-EGFR re-challenge on survival...
Association of co-occurring KRAS and gain of function TP53 mutations with aggressive metastasis through comprehensive genomic profiling of pancreatic ductal adenocarcinoma.
e16379 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of malignancy. Although tissue genomics has been valuable i...
The combination of naxitamab with or without sintilimab (anti-PD-1) for the treatment of refractory/progressive neuroblastoma: A prospective, non-randomized, multicenter trial.
e22014 Background: Although significant advancements have been made in the treatment of neuroblastoma (NB), many patients continue to develop refractory o...
A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.
TPS4220 Background: Cholangiocarcinoma is a rare and aggressive group of gastrointestinal cancers. For early-stage disease following curative resection, c...
Assessing venous thromboembolism risk in HR+/HER2- breast cancer patients receiving CDK4/6 inhibitors: Insights from real-world data in the Middle East.
e13049 Background: Breast cancer is the most frequently diagnosed cancer in women, and hormone receptor-positive, HER2-negative (HR+/HER2-) is the most co...
Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center.
8635 Background: Lung cancer remains the deadliest solid tumor, with non-small cell lung cancer (NSCLC) accounting for 80–85% of cases. Patients enrolling...